Literature DB >> 12057053

Advanced cervical cancer.

S K Gibbons1, H M Keys.   

Abstract

Several large, prospectively randomized clinical trials run by multi-institutional cooperative groups have established that the best treatment for advanced cancer of the cervix is primary radiotherapy with concurrent, cisplatin-based chemotherapy. In fact, patients with earlier stage cervix cancer with poor prognostic indicators (large, bulky tumors, positive pelvic lymph nodes, or unexpected parametrial disease at the time of surgery) also show a survival benefit with this approach. Adequate radiation dosing (both external beam and intracavitary) is essential. The additional benefit of periaortic lymph node irradiation is debated, but generally accepted, for patients with locally advanced disease or pelvic lymph node involvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12057053     DOI: 10.1007/s11864-000-0060-7

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  11 in total

1.  High dose rate transperineal interstitial brachytherapy for cervical cancer: high pelvic control and low complication rates.

Authors:  D J Demanes; R R Rodriguez; D D Bendre; T L Ewing
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

2.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

Authors:  M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

3.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

4.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

Authors:  C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Iridium-192 transperineal interstitial brachytherapy for locally advanced or recurrent gynecological malignancies.

Authors:  A K Gupta; F A Vicini; A J Frazier; D C Barth-Jones; G K Edmundson; E Mele; G S Gustafson; A A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

6.  Accelerated hyperfractionated radiotherapy for locally advanced cervix cancer.

Authors:  C MacLeod; D Bernshaw; S Leung; K Narayan; I Firth
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

7.  Hyperfractionation in carcinoma of the cervix: tumor control and late bowel complications.

Authors:  F R Viswanathan; C Varghese; A Peedicayil; J Lakshmanan; V P Narayan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

8.  First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study.

Authors:  M S Piver; S A Ghamande; G H Eltabbakh; C O'Neill-Coppola
Journal:  Gynecol Oncol       Date:  1999-12       Impact factor: 5.482

9.  Hyperfractionated radiation therapy plus chemotherapy in locally advanced cervical cancer: results of two phase I dose-escalation Gynecologic Oncology Group trials.

Authors:  A R Calkins; C R Harrison; W C Fowler; H Gallion; C E Mangan; N Husseinzadeh; R D Alvarez; B Mychalczak; E Podczaski
Journal:  Gynecol Oncol       Date:  1999-12       Impact factor: 5.482

10.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.